ProQR Therapeutics N.V. (PRQR) Stock Forecast
PRQR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.89 / 5 from 9 analysts
- Price target
- $7.78 average of analyst targets
- Upside to target
- +493.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.11
- 52-week range
- $1.31 – $3.05
PRQR analyst ratings
9 analystsNumber of analysts at each rating.
PRQR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRQR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.11 | −$0.10 | −$0.12 | +12.1% | 2 |
| Current fiscal year (2026) | −$0.45 | −$0.53 | −$0.38 | −$0.46 | −29.3% | 2 |
| Next fiscal year (2027) | −$0.46 | −$0.54 | −$0.39 | −$0.45 | −2.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRQR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.9M | $3.2M | $5.8M | +46.7% | 5 |
| Current fiscal year (2026) | $20.5M | $11.9M | $24.3M | +8.2% | 6 |
| Next fiscal year (2027) | $18.4M | $0 | $25.9M | −10.3% | 6 |
PRQR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRQR revenue: reported and forecast
PRQR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.14 | −$0.11 | −$0.11 | −$0.11 | −22.6% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.60 | −$0.60 | −$0.46 | −$0.46 | −$0.45 | −25.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.68 | −$0.68 | −$0.47 | −$0.47 | −$0.46 | −31.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRQR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRQR beat in 9 of 12.
What analysts expect from PRQR
9 analysts cover ProQR Therapeutics; their consensus rating is strong buy (4.89 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.78, 493.7% above the latest close of $1.31. Analysts expect earnings of −$0.45 per share for 2026, −29.3% from a year earlier. For 2027 the average estimate is −$0.46 per share on revenue of $18.4 million. ProQR Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: PRQR income statement, PRQR key metrics, PRQR chart. See the PRQR stock overview for the latest quote and news.
PRQR forecast FAQ
What is ProQR Therapeutics's price target?
The average analyst price target for ProQR Therapeutics is $7.78, 493.7% above the latest close of $1.31.
Is ProQR Therapeutics a buy, hold or sell?
Of 9 analysts covering ProQR Therapeutics, 8 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ProQR Therapeutics's EPS forecast?
Analysts forecast −$0.45 per share for 2026 (range −$0.53 to −$0.38); for 2027 the estimate is −$0.46.
What is ProQR Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $20.5 million, growth of 8.2%; for 2027 it is $18.4 million.
When does ProQR Therapeutics report earnings?
ProQR Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.11.
Does ProQR Therapeutics usually beat earnings estimates?
ProQR Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.